Multidrug resistance in cancer: Role of ATP-dependent transporters

被引：4599

作者：

Gottesman, MM ^{[1
]}

Fojo, T ^{[1
]}

Bates, SE ^{[1
]}

机构：

[1] Ctr Canc Res, Lab Cell Biol & Canc Therapeut Branch, NIH, Bethesda, MD 20892 USA

来源：

NATURE REVIEWS CANCER | 2002年 / 2卷 / 01期

关键词：

D O I：

10.1038/nrc706

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs - a trait known as multidrug resistance - remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.

引用

页码：48 / 58

页数：11

共 170 条

[1]

Abolhoda A, 1999, CLIN CANCER RES, V5, P3352

[2]

ABRAHAM J, 2001, P AN M AM SOC CLIN, V20, P287

[3] Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar) [J].

Advani, R ;

Saba, HI ;

Tallman, MS ;

Rowe, JM ;

Wiernik, PH ;

Ramek, J ;

Dugan, K ;

Lum, B ;

Villena, J ;

Davis, E ;

Paietta, E ;

Litchman, M ;

Sikic, BI ;

Greenberg, PL .

BLOOD, 1999, 93 (03) :787-795

[4]

Advani R, 2001, CLIN CANCER RES, V7, P1221

[5]

Allikmets R, 1998, CANCER RES, V58, P5337

[6] Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].

Ambudkar, SV ;

Dey, S ;

Hrycyna, CA ;

Ramachandra, M ;

Pastan, I ;

Gottesman, MM .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398

[7]

Baekelandt MM, 2000, ANTICANCER RES, V20, P1061

[8] EXPRESSION OF P-GLYCOPROTEIN IN HIGH-GRADE OSTEOSARCOMAS IN RELATION TO CLINICAL OUTCOME [J].

BALDINI, N ;

SCOTLANDI, K ;

BARBANTIBRODANO, G ;

MANARA, MC ;

MAURICI, D ;

BACCI, G ;

BERTONI, F ;

PICCI, P ;

SOTTILI, S ;

CAMPANACCI, M ;

SERRA, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (21) :1380-1385

[9] PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE [J].

BARTLETT, NL ;

LUM, BL ;

FISHER, GA ;

BROPHY, NA ;

EHSAN, MN ;

HALSEY, J ;

SIKIC, BI .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :835-842

[10]

Beck WT, 1996, CANCER RES, V56, P3010

← 1 2 3 4 5 6 7 8 9 10 →